Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Classical hematology 2

Conditions

Anemia 2Primary Myelofibrosis 1Myelodysplastic Syndromes 1

Interventions

fludarabine phosphate 58Cyclophosphamide 54Epoetin Alfa 43Cyclosporine 43Busulfan 43Peripheral Blood Stem Cell Transplantation 39Mycophenolic Acid 34Darbepoetin alfa 33Antilymphocyte Serum 31Whole-Body Irradiation 30Cytarabine 30Filgrastim 29Methotrexate 26Tacrolimus 25Radiotherapy 25Melphalan 24fludarabine 21Methylprednisolone 17Cord Blood Stem Cell Transplantation 17Etoposide 14Granulocyte Colony-Stimulating Factor 13Daunorubicin 13Rivaroxaban 12apixaban 11Thiotepa 11sargramostim 10epoetin beta 10Dalteparin 10eltrombopag 9Alemtuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × luspatercept × Classical hematology × Clear all
NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Celgene

Phase 2 Completed
95 enrolled 32 charts
Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

NCT02631070 2021-12-17

MEDALIST

Celgene

Phase 3 Completed
229 enrolled 36 charts 1 FDA
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡